Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
暂无分享,去创建一个
C. Sessa | S. Rothschild | I. Colombo | O. Gautschi | P. Froesch | Qiyu Li | M. Früh | E. Oppliger Leibundgut | Y. Metaxas | C. Rusterholz | M. Mark | D. König | S. Schmid | G. Godar